Zydus Lifesciences has received final approval from the US Food and Drug Administration (USFDA) to market Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL) single-dose vials, a company statement announced.

The injection is used to treat partial-onset seizures. It is also used with other medicines to treat primary generalized tonic-clonic seizures.

Click for more articles on USFDA

The statement added that it acts on the central nervous system (CNS) to reduce the number and severity of seizures.

It also said that the drug will be manufactured at the group’s injectable manufacturing facility at Jarod, India.

9th edition of IP released containing 3,152 Monographs

PCI to introduce One Nation One Cadre guideline for pharmacy across the country

QR code could curb circulation of fake, spurious and substandard medicines

IPGA Telangana organizes National level Symposium on Medical Device Regulation in India

USFDA gives final approval for Seizure injections

Public Service Commission yet to fill up vacant Drugs Inspector posts

These 4 countries accept Indian Pharmacopoeia (IP) as book of standard

DCGI approves India’s first mRNA vaccine against C-19

Govt in talks with UAE to recognise Indian Pharmacopoeia

Drug Alert: NSQ Drugs Lists

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/07/03/usfda-gives-final-approval-for-lacosamide-injection/